Up­dat­ed: Zen­tal­is lays off 40% of staff, whit­tles down in­di­ca­tions for WEE1 in­hibitor

Zen­tal­is Phar­ma­ceu­ti­cals is ax­ing about 40% of its staff and re­fo­cus­ing its on­ly pipeline can­di­date on a small­er group of ovar­i­an can­cer pa­tients.

The San …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER